[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Fotiadis C, Georgopoulos I, Stoidis C, Patapis P: Primary tumors of the spleen. Int J Biomed Sci; 2009 Jun;5(2):85-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lymphoid tumors include Hodgkin's and non Hodgkin's lymphoma, histiocytic lymphoma and plasmacytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23675122.001).
  • [ISSN] 1550-9702
  • [Journal-full-title] International journal of biomedical science : IJBS
  • [ISO-abbreviation] Int J Biomed Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3614769
  • [Keywords] NOTNLM ; metastatic / primary / spleen / tumors
  •  go-up   go-down


2. Zonenberg A, Zarzycki W, Leoniak M: [The effect of Chernobyl accident on the development of malignant diseases--situation after 20 years]. Endokrynol Pol; 2006 May-Jun;57(3):244-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data obtained from the regions near Chernobyl showed no increased risk of other types of malignancy (leukaemia, Hodgkin's and non Hodgkin's lymphoma) in 1986-1996.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832789.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Radioactive Fallout
  • [Number-of-references] 70
  •  go-up   go-down


3. Grant WB, Boucher BJ: Current impediments to acceptance of the ultraviolet-B-vitamin D-cancer hypothesis. Anticancer Res; 2009 Sep;29(9):3597-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are about 14 types of cancer for which it seems to apply: bladder, breast, colon, endometrial, esophageal, gallbladder, gastric, ovarian, pancreatic, rectal, renal and vulvar cancer and both Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667154.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 98
  •  go-up   go-down


Advertisement
4. Grant WB: How strong is the evidence that solar ultraviolet B and vitamin D reduce the risk of cancer?: An examination using Hill's criteria for causality. Dermatoendocrinol; 2009 Jan;1(1):17-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results for breast and colorectal cancer satisfy the criteria best, but there is also good evidence that other cancers do as well, including bladder, esophageal, gallbladder, gastric, ovarian, rectal, renal and uterine corpus cancer, as well as Hodgkin's and non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5596-602 [18936471.001]
  • [Cites] Urology. 2008 Mar;71(3):531-5 [18342203.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1690-4 [18092326.001]
  • [Cites] Carcinogenesis. 2008 Jan;29(1):93-9 [17974532.001]
  • [Cites] Curr Med Res Opin. 2008 Jan;24(1):139-49 [18034918.001]
  • [Cites] Epidemiol Infect. 2008 Jan;136(1):1-9 [17553179.001]
  • [Cites] J Epidemiol Community Health. 2008 Jan;62(1):69-74 [18079336.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):12-5 [17967529.001]
  • [Cites] Ann Epidemiol. 2007 Dec;17(12):956-63 [18022535.001]
  • [Cites] Prev Med. 2007 Nov;45(5):327-31 [17395256.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1889-93 [17855710.001]
  • [Cites] Int J Health Geogr. 2007;6:34 [17651508.001]
  • [Cites] Eur J Dermatol. 2007 Sep-Oct;17(5):428-34 [17673388.001]
  • [Cites] Acta Pharmacol Sin. 2007 Sep;28(9):1373-82 [17723171.001]
  • [Cites] Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):236-42 [17696738.001]
  • [Cites] Prostate. 2007 Sep 1;67(12):1362-70 [17624920.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1701-12 [17540555.001]
  • [Cites] Dis Markers. 2007;23(4):247-59 [17627060.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):123-8 [17551495.001]
  • [Cites] Am J Clin Nutr. 2007 Jun;85(6):1586-91 [17556697.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1283-6 [17548698.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10):1554-9 [17453003.001]
  • [Cites] Ann Neurol. 2007 Apr;61(4):288-99 [17444504.001]
  • [Cites] Breast Cancer Res Treat. 2007 May;102(3):323-8 [17028983.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):708-11 [17368188.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):668-74 [17208438.001]
  • [Cites] Am J Clin Nutr. 2007 Mar;85(3):860-8 [17344510.001]
  • [Cites] Lung Cancer. 2007 Mar;55(3):263-70 [17207891.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):479-85 [17290055.001]
  • [Cites] Am J Prev Med. 2007 Mar;32(3):210-6 [17296473.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1123-8 [17149699.001]
  • [Cites] Am J Prev Med. 2006 Dec;31(6):512-4 [17169713.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2467-72 [17132768.001]
  • [Cites] BMC Cancer. 2006;6:264 [17096841.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10213-9 [17047087.001]
  • [Cites] Epidemiol Infect. 2006 Dec;134(6):1129-40 [16959053.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2705-9 [16981191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1688-95 [16985031.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1091-101 [16933060.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1530-6 [16671100.001]
  • [Cites] ChemMedChem. 2006 Aug;1(8):783-802 [16902931.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2687-99 [16886679.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2605-14 [16886670.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] J Natl Med Assoc. 2006 Mar;98(3):357-64 [16573299.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):669-83 [16481635.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2303-9 [16214909.001]
  • [Cites] J Nutr. 2005 Oct;135(10):2350-4 [16177194.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):571-4 [16136030.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3274-8 [18990771.001]
  • [Cites] Am J Pathol. 2008 Nov;173(5):1589-90 [18948436.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2398-407 [18816636.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41 [18525006.001]
  • [Cites] Anticancer Res. 2008 May-Jun;28(3B):1955-63 [18630488.001]
  • [Cites] BMJ. 2008 Jun 14;336(7657):1318-9 [18556276.001]
  • [Cites] Eur J Surg Oncol. 2008 Jul;34(7):765-70 [18160246.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2984-91 [18565885.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):796-804 [18505967.001]
  • [Cites] Am J Pathol. 2008 Jun;172(6):1717-28 [18483213.001]
  • [Cites] Cancer Causes Control. 2008 Jun;19(5):527-35 [18219582.001]
  • [Cites] Diabetes Care. 2008 Apr;31(4):701-7 [18235052.001]
  • [Cites] Adv Exp Med Biol. 2008;624:104-16 [18348451.001]
  • [Cites] Adv Exp Med Biol. 2008;624:43-54 [18348446.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):195-9 [15687362.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):429-40 [15539405.001]
  • [Cites] Health Phys. 2004 Nov;87(5):532-8 [15551791.001]
  • [Cites] Proc R Soc Med. 1965 May;58:295-300 [14283879.001]
  • [Cites] Photochem Photobiol. 1999 Aug;70(2):243-7 [10461463.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):425-32 [9794175.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):323-31 [9031113.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 6;88(21):1560-70 [8901854.001]
  • [Cites] Sci Am. 1996 Jul;275(1):52-3, 56-9 [8658110.001]
  • [Cites] BMJ. 1996 May 4;312(7039):1128-31 [8620128.001]
  • [Cites] Ann Med. 1995 Oct;27(5):565-8 [8541033.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 5;86(1):33-8 [8271280.001]
  • [Cites] Int J Epidemiol. 1994 Dec;23(6):1133-6 [7721513.001]
  • [Cites] Lancet. 1985 Feb 9;1(8424):307-9 [2857364.001]
  • [Cites] Jpn J Clin Oncol. 1985 Jun;15(2):403-13 [4021121.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Rev Infect Dis. 1982 Nov-Dec;4(6):1270-4 [6818657.001]
  • [Cites] Lancet. 1981 Nov 28;2(8257):1185-90 [6118627.001]
  • [Cites] Lancet. 1982 Jan 9;1(8263):74-6 [6119494.001]
  • [Cites] Int J Epidemiol. 1980 Sep;9(3):227-31 [7440046.001]
  • [Cites] Int J Cancer. 1975 Apr 15;15(4):617-31 [1140864.001]
  • [Cites] Nutr Cancer. 2004;48(2):115-23 [15231446.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1042-51 [15184262.001]
  • [Cites] Cancer Causes Control. 2004 Mar;15(2):149-58 [15017127.001]
  • [Cites] Eur Urol. 2004 Mar;45(3):271-9 [15036670.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):59-64 [14744734.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):694-704 [14710348.001]
  • [Cites] Recent Results Cancer Res. 2003;164:99-110 [12908448.001]
  • [Cites] Recent Results Cancer Res. 2003;164:371-7 [12899536.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] Ann Epidemiol. 2003 Jul;13(6):395-404 [12875796.001]
  • [Cites] J Cell Biochem. 2003 Feb 1;88(2):363-71 [12520538.001]
  • [Cites] Br J Dermatol. 2002 Aug;147(2):197-213 [12174089.001]
  • [Cites] Occup Environ Med. 2002 Apr;59(4):257-62 [11934953.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1867-75 [11920550.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):272-81 [11815987.001]
  • [Cites] Lung Cancer. 2002 Jan;35(1):43-51 [11750712.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):837-46 [11312434.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Aug;14(4):797-807, viii [10949774.001]
  • [Cites] Health Place. 1998 Dec;4(4):355-64 [10670982.001]
  • [Cites] Curr Pharm Des. 2000 May;6(7):717-32 [10828303.001]
  • [Cites] Eur J Clin Nutr. 1999 Dec;53(12):920-6 [10602348.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Feb;4(2):80-90 [18212810.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2 [18202430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):668-73 [18180454.001]
  • [Cites] Ann Epidemiol. 1993 Jan;3(1):103-10 [8287144.001]
  • [Cites] Prev Med. 1990 Nov;19(6):614-22 [2263572.001]
  • [Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1307-11 [2241107.001]
  • (PMID = 20046584.001).
  • [ISSN] 1938-1980
  • [Journal-full-title] Dermato-endocrinology
  • [ISO-abbreviation] Dermatoendocrinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2715209
  • [Keywords] NOTNLM ; association / breast cancer / colon cancer / dose-response / ecologic / mechanisms / observational / supplements / viral infections
  •  go-up   go-down


5. Grant WB, Garland CF, Gorham ED: An estimate of cancer mortality rate reductions in Europe and the US with 1,000 IU of oral vitamin D per day. Recent Results Cancer Res; 2007;174:225-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solar ultraviolet B (UVB) irradiance and/or vitamin D have been found inversely correlated with incidence, mortality, and/or survival rates for breast, colorectal, ovarian, and prostate cancer and Hodgkin's and non-Hodgkin's lymphoma.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302200.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 86
  •  go-up   go-down


6. Wedgwood A, Younes A: Targeting lymphoma cells and their microenvironment with novel antibodies. Clin Lymphoma Myeloma; 2006 Oct;7 Suppl 1:S33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting lymphoma cells and their microenvironment with novel antibodies.
  • Novel monoclonal antibodies are currently being evaluated and have been shown to have significantly influenced the treatment of Hodgkin's and non-Hodgkin's lymphoma.
  • It is of the utmost importance to reduce treatment-related toxicity and, hopefully, improve the cure rate of lymphoma.
  • Continued investigation is encouraged to combine monoclonal antibodies with other targeted therapies and incorporate their use into standards of care in the treatment of lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma / immunology. Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101071.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20
  • [Number-of-references] 92
  •  go-up   go-down


7. Völk M, Strotzer M: [Diagnostic imaging of splenic disease]. Radiologe; 2006 Mar;46(3):229-43; quiz 244
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioma represents the most common primary benign tumor, and lymphoma the most common primary malignant tumor of the spleen.
  • Diagnostic imaging does not a allow safe differentiation between Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 1997 Jul;52(7):535-40 [9240707.001]
  • [Cites] Eur Radiol. 1998;8(4):553-62 [9569321.001]
  • [Cites] Bildgebung. 1994 Sep;61(3):210-5 [7987064.001]
  • [Cites] Radiographics. 1994 Mar;14 (2):307-32 [8190956.001]
  • [Cites] J Magn Reson Imaging. 1994 Sep-Oct;4(5):659-68 [7981510.001]
  • [Cites] Radiology. 1990 Mar;174(3 Pt 1):803-7 [2406785.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):567-71 [11995499.001]
  • [Cites] Abdom Imaging. 1999 Jul-Aug;24(4):414-7 [10390570.001]
  • [Cites] J Thorac Imaging. 1991 Apr;6(2):69-71 [1856904.001]
  • [Cites] Clin Radiol. 1994 Feb;49(2):115-7 [8124888.001]
  • [Cites] Radiology. 1997 Jan;202(1):166-72 [8988207.001]
  • [Cites] AJR Am J Roentgenol. 1990 Oct;155(4):805-10 [2119113.001]
  • [Cites] Br J Radiol. 1981 Apr;54(640):335-8 [7225721.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):293-8 [1729784.001]
  • [Cites] J Comput Assist Tomogr. 1997 May-Jun;21(3):369-72 [9135642.001]
  • [Cites] AJR Am J Roentgenol. 1986 May;146(5):997-1004 [3008544.001]
  • [Cites] Radiologe. 2005 Dec;45(12):1124-8 [16249923.001]
  • [Cites] Radiographics. 1993 May;13(3):597-610 [8316667.001]
  • (PMID = 16435091.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 24
  •  go-up   go-down


8. Barr P, Fisher R, Friedberg J: The role of bortezomib in the treatment of lymphoma. Cancer Invest; 2007 Dec;25(8):766-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of bortezomib in the treatment of lymphoma.
  • Among the various cancers susceptible to proteasome inhibition are the non-Hodgkin's lymphomas.
  • Mantle cell lymphoma appears to be particularly sensitive, leading to the FDA approval of bortezomib in patients who have received at least one prior therapy.
  • In this review, we will detail the clinical results and ongoing trials utilizing bortezomib in Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma / drug therapy. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use
  • [MeSH-minor] Bortezomib. Hodgkin Disease / drug therapy. Humans. Lymphoma, Mantle-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058474.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 86
  •  go-up   go-down


9. Kasamon YL, Wahl RL: FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol; 2008 Mar;20(2):206-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.
  • PURPOSE OF REVIEW: The prognostic utility of midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography (F-FDG PET) has become widely appreciated in aggressive B-cell non-Hodgkin's lymphoma and, more recently, in Hodgkin's lymphoma.
  • How to tailor therapy based on the midtreatment PET result is the focus of current trials and is presently being defined for both Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2005 Jul;16(7):1160-8 [15939713.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4652-61 [15837965.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4643-51 [15837966.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4634-42 [15837968.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4574-6 [15837972.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1296-300 [16766583.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1267-73 [16883004.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):965-72 [16920563.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):759-67 [16871391.001]
  • [Cites] J Nucl Med. 2006 Oct;47(10):1643-8 [17015900.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Nov;28(11):711-4 [17114956.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2678-87 [17063502.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:19S-27S [17204717.001]
  • [Cites] Blood. 2007 Jan 15;109(2):486-91 [17003382.001]
  • [Cites] Blood. 2007 Feb 1;109(3):905-9 [17018856.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] Acad Radiol. 2007 Mar;14(3):330-9 [17307666.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):399-402 [16514616.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):338-46 [17400393.001]
  • [Cites] Cancer. 2007 Jun 15;109(12):2481-9 [17497648.001]
  • [Cites] Radiology. 2007 Jul;244(1):257-62 [17581905.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3746-52 [17646666.001]
  • [Cites] Nucl Med Commun. 2007 Oct;28(10):798-803 [17728610.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1361-9 [17623832.001]
  • [Cites] J Nucl Med. 2007 Oct;48(10):1626-32 [17873129.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Hematology. 2007 Oct;12(5):423-30 [17852456.001]
  • [Cites] Ann Oncol. 1999 Oct;10(10):1185-9 [10586335.001]
  • [Cites] J Nucl Med. 2000 Jun;41(6):999-1005 [10855624.001]
  • [Cites] Haematologica. 2000 Jun;85(6):613-8 [10870118.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):543-53 [11342337.001]
  • [Cites] Leukemia. 2002 Feb;16(2):260-7 [11840293.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(2):103-11 [12132049.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1356-63 [12196360.001]
  • [Cites] J Nucl Med. 2003 Feb;44(2):170-6 [12571205.001]
  • [Cites] Blood. 2003 May 15;101(10):3875-6 [12531812.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S82-8 [12719922.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] Blood. 2003 Jul 1;102(1):53-9 [12609836.001]
  • [Cites] Chest. 2003 Aug;124(2):608-13 [12907550.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):282-7 [14531910.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1574-97 [14579100.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1304-15 [14607760.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):85-92 [15061202.001]
  • [Cites] Radiology. 2004 Sep;232(3):823-9 [15273335.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):38-45 [3806158.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Radiology. 1995 Jul;196(1):167-73 [7784562.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Radiology. 2005 Dec;237(3):1038-45 [16304117.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):544-8 [16446326.001]
  • [Cites] Haematologica. 2006 Apr;91(4):490-5 [16533726.001]
  • [Cites] Haematologica. 2006 Apr;91(4):475-81 [16585014.001]
  • [Cites] J Nucl Med. 2006 Apr;47(4):603-8 [16595493.001]
  • [Cites] Bone Marrow Transplant. 2006 Aug;38(3):211-6 [16770314.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):48-55 [9440722.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):173-80 [9440740.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4464-71 [9616140.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Cancer Chemother Rep. 1964 Feb;35:1-111 [14117037.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3483-9 [15315964.001]
  • [Cites] Mol Imaging Biol. 2004 Nov-Dec;6(6):411-6 [15564152.001]
  • (PMID = 18300772.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA124465-01A2; United States / NCI NIH HHS / CA / K23 CA124465; United States / NCI NIH HHS / CA / K23 CA124465-01A2
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 78
  • [Other-IDs] NLM/ NIHMS281899; NLM/ PMC3652336
  •  go-up   go-down


10. Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S, Alavi A: Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun; 2006 Jan;27(1):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?
  • OBJECTIVES: To assess the usefulness of [18F]fluorodeoxyglucose positron emission tomography in the detection of bone marrow involvement in malignant lymphoma, and its impact in clinical management.
  • METHODS: One hundred and six consecutive patients with a confirmed diagnosis of lymphoma, referred for staging or restaging of Hodgkin's lymphoma (n=18) or non-Hodgkin's lymphoma (n=88), were reviewed retrospectively.
  • The assessment of bone marrow involvement by lymphoma was confirmed by histology and/or progression of bone marrow lesions in clinical follow-up.
  • Ten cases of non-Hodgkin's lymphoma and two cases of Hodgkin's lymphoma with positive positron emission tomography results and an initial negative bone marrow biopsy showed clinical progression of the bone marrow lesions and/or subsequent positive histology.
  • In four cases of follicular lymphoma, the bone marrow biopsy was positive and the positron emission tomography scan was normal.
  • CONCLUSIONS: Positron emission tomography and bone marrow biopsy are complementary in assessing the presence of bone marrow involvement in patients with malignant lymphoma.
  • In our series, positron emission tomography was more sensitive than bone marrow biopsy in Hodgkin's and non-Hodgkin's lymphoma, except in follicular lymphoma.
  • [MeSH-major] Biopsy, Needle / methods. Bone Marrow / pathology. Bone Marrow / radionuclide imaging. Fluorodeoxyglucose F18. Ilium / pathology. Lymphoma / pathology. Lymphoma / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340718.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


11. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D: Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer; 2005 Apr 25;92(8):1352-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
  • There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma.
  • We evaluated the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) in 41 heavily pretreated patients with relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma / drug therapy. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1994;5 Suppl 2:91-5 [7515652.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):543-9 [8573532.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9 [7481849.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Bone Marrow Transplant. 1997 Jul;20(1):21-6 [9232251.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):525-9 [9261520.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3264-9 [9779700.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3562-8 [9808548.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):351-4 [10355582.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):981-90 [10362105.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):943-7 [10509156.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3786-92 [10577850.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Ann Oncol. 2000 May;11(5):595-7 [10907954.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] Biochem Pharmacol. 2001 Jun 1;61(11):1401-8 [11331076.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):786-92 [11843810.001]
  • [Cites] N Engl J Med. 2002 May 2;346(18):1417-8 [11986425.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):311-5 [12201493.001]
  • [Cites] Gynecol Oncol. 2003 Jan;88(1):17-21 [12504621.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):970-7 [12648066.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Dec;17(6):621-30 [12537665.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1963-70 [12799644.001]
  • [Cites] Rev Mal Respir. 2003 Apr;20(2 Pt 1):201-6 [12844017.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):978-82 [12942565.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):363-8 [15140550.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2424-9 [15136597.001]
  • [Cites] Oncology. 2004;66(3):197-200 [15218310.001]
  • [Cites] Clin Lymphoma. 2004 Jun;5(1):45-9 [15245607.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):406-13 [1740680.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • (PMID = 15812553.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC2361993
  •  go-up   go-down


12. de Vos S: Historical Overview and Current State of Art in Diagnosis and Treatment of Hodgkin's and Non-Hodgkin's Lymphoma. PET Clin; 2006 Jul;1(3):203-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Historical Overview and Current State of Art in Diagnosis and Treatment of Hodgkin's and Non-Hodgkin's Lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27157360.001).
  • [ISSN] 1556-8598
  • [Journal-full-title] PET clinics
  • [ISO-abbreviation] PET Clin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Taylor MD, Jones DR: Genetic markers of mediastinal tumors. Thorac Surg Clin; 2009 Feb;19(1):17-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These new techniques have enabled scientists to uncover differential gene expression patterns between subtypes of thymomas, correlate tumor marker expression with germ cell tumors, and determine a link between the NF-kappaB and JAK/STAT pathways with Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chromosome Aberrations. Humans. Lymphoma / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Neoplasms, Nerve Tissue / genetics. Thymoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288817.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers
  • [Number-of-references] 47
  •  go-up   go-down


14. Bonnet C, Beguin Y, Fassotte MF, Seidel L, Luyckx F, Fillet G: Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. Eur J Haematol; 2007 May;78(5):399-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
  • BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome.
  • PATIENTS AND METHODS: Ninety-nine patients with NHL or Hodgkin's disease (HD) underwent serum CA125 assessment at diagnosis.
  • [MeSH-major] CA-125 Antigen / blood. Hodgkin Disease / blood. Lymphoma, Non-Hodgkin / blood

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419741.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


15. Flinn IW, Berdeja JG: Blood and bone marrow transplantation for patients with Hodgkin's and non-Hodgkin's lymphoma. Cancer Treat Res; 2006;131:251-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood and bone marrow transplantation for patients with Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Blood Transfusion. Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy


16. Kostakoglu L: Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging; 2008 Aug;35(8):1413-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Outcome Assessment (Health Care) / methods. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Sep;13(9):1356-63 [12196360.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 3;93(1):22-30 [11136838.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Oct;25(10):1441-9 [2480242.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4652-61 [15837965.001]
  • [Cites] J Clin Oncol. 1988 Mar;6(3):425-33 [2450970.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):542-7 [7837388.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Haematologica. 2007 Jun;92(6):778-83 [17550850.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7067-71 [3191483.001]
  • [Cites] Cancer Treat Rep. 1986 Jan;70(1):163-9 [3510732.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:253-8 [17124069.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):66-76 [16399588.001]
  • [Cites] Lancet. 2003 Jul 12;362(9378):139-46 [12867117.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] Ann Oncol. 2003 Jan;14 (1):123-30 [12488304.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Nucl Med. 2007 Oct;48(10 ):1626-32 [17873129.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1296-300 [16766583.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3483-9 [15315964.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):682-8 [12601498.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):534-42 [8636768.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):227-35 [18088400.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Mar;4(3):210-30 [16507269.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):543-53 [11342337.001]
  • [Cites] Haematologica. 2006 Apr;91(4):475-81 [16585014.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Nov;28(11):711-4 [17114956.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1304-15 [14607760.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2 Suppl 4):3-9 [12728402.001]
  • [Cites] Blood. 1989 Jan;73(1):47-56 [2462943.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2796-802 [9704732.001]
  • [Cites] Haematologica. 2006 Apr;91(4):490-5 [16533726.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):104-9 [3589684.001]
  • [Cites] Curr Treat Options Oncol. 2003 Aug;4(4):297-305 [12943610.001]
  • [Cites] J Clin Oncol. 1986 Feb;4(2):147-53 [2418166.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3746-52 [17646666.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] N Engl J Med. 1995 Apr 20;332(16):1045-51 [7898521.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1160-8 [15939713.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):474-80 [14962711.001]
  • [Cites] Leuk Lymphoma. 2007 Aug;48(8):1522-30 [17701583.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4634-42 [15837968.001]
  • [Cites] J Clin Oncol. 1986 Feb;4(2):160-4 [2418167.001]
  • [Cites] J Clin Oncol. 1985 May;3(5):637-40 [3998780.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):586-92 [8636775.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1130-4 [1515634.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2678-87 [17063502.001]
  • [Cites] Leuk Lymphoma. 2007 Aug;48(8):1539-47 [17701585.001]
  • [Cites] NCI Monogr. 1987;(5):77-80 [2448657.001]
  • (PMID = 18385996.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Grant WB: Hypothesis--ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. Photochem Photobiol; 2008 Mar-Apr;84(2):356-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cancers with seemingly important risk from viral infections important in winter, based on correlations with increasing latitude in the United States, an index of wintertime solar ultraviolet-B dose and vitamin D, are bladder, prostate, testicular and thyroid cancer, Hodgkin's and non-Hodgkin's lymphoma, and, perhaps, gastric cancer.


18. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, SPAT Group: Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect; 2010 Dec;138(12):1804-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More modestly increased rates of IPD were found in those with chronic lymphocytic leukaemia, acute myeloid leukaemia, acute lymphoblastic leukaemia, and Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429967.001).
  • [ISSN] 1469-4409
  • [Journal-full-title] Epidemiology and infection
  • [ISO-abbreviation] Epidemiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


19. Krishnan A, Levine AM: Malignancies in women with HIV infection. Womens Health (Lond); 2008 Jul;4(4):357-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of other types of malignancies, such as Hodgkin's and non-Hodgkin's lymphoma, is also increased in HIV-infected individuals.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active / statistics & numerical data. Comorbidity. Disease-Free Survival. Female. Hodgkin Disease / epidemiology. Humans. Lymphoma, Non-Hodgkin / epidemiology. Risk Factors


20. Divgi C: Imaging: staging and evaluation of lymphoma using nuclear medicine. Semin Oncol; 2005 Feb;32(1 Suppl 1):S11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging: staging and evaluation of lymphoma using nuclear medicine.
  • The management of lymphoma is dependent on accurate staging of the disease and evaluation of histology and other risk factors.
  • Many studies have indicated that FDG-PET is as good as or better than 67 Ga-SPECT for the detection of lymphoma.
  • At present, FDG-PET scanning is not routinely available in all institutions; however, a role can be indicated for FDG-PET in several areas of lymphoma management, including initial staging, predicting response to therapy (during and following chemotherapy), and identification of residual tumor.
  • This article examines the role of the different imaging techniques available and the use of these techniques in the staging and evaluation of patients with Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / radionuclide imaging. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786021.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A: Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum; 2010 Aug;62(8):2517-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Half of the malignancies reported were lymphomas and included both Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2010 Aug;62(8):2183-4 [20506203.001]
  • (PMID = 20506368.001).
  • [ISSN] 1529-0131
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


22. Martin S, Ulrich C, Munsell M, Taylor S, Lange G, Bleyer A: Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist; 2007 Jul;12(7):816-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data on 270 patients with the six most common cancer types in this cohort (leukemia, Hodgkin's and non-Hodgkin's lymphoma, sarcoma, brain tumors, thyroid cancer) were retrospectively collected in 2004.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673613.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Pagano L, Caira M, Nosari A, Rossi G, Locatelli F, Viale P, Aversa F, Hema E-Chart Group Italy: Hema e-Chart: Italian Registry for prospective analysis of epidemiology, management and outcome of febrile events in patients with hematological malignancies. J Chemother; 2010 Feb;22(1):20-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its aim is to improve the speed, quality and integration of information related to subjects with febrile event, ultimately resulting in improving patients' care.Patients included adults and children with acute and chronic myeloid or lymphoid leukemia, Hodgkin's and non-Hodgkin's lymphoma, myelodysplastic syndrome, or multiple myeloma.

  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20227988.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Investigator] Levis A; Leoni P; Liso V; Baccarani M; Cortellazzo S; Rossi G; Russo D; La Nasa G; Storti S; Giustolisi R; Morabito F; Cuneo A; Bosi A; Capalbo SF; Cascavilla N; Ghio R; Carella A; Brugiatelli M; Ciceri F; Martinelli G; Morra E; Pogliani E; Mettivier V; Carli M; Abbadessa V; Musso M; Aricò M; Lazzarino M; Visani G; Fioritoni G; Di Bartolomeo P; Vallisa D; Petrini M; Favre C; Olivieri A; Gugliotta L; Leone G; Amadori S; De Rossi G; De Fabritiis P; Majolino I; D'Arco A; Lauria F; Mazza P; Fagioli F; Gherlinzoni F; Chesesi T; Rodeghiero F
  •  go-up   go-down


24. Altintas A, Cil T, Pasa S, Danis R, Kilinc I, Ayyildiz O, Muftuoglu E: Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non-Hodgkin's lymphoma: a single center experience. Minerva Med; 2008 Feb;99(1):7-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non-Hodgkin's lymphoma: a single center experience.
  • AIM: There is an increased risk of lymphoma subsequent to autoimmune conditions.
  • In this study, the association of autoimmunity and related autoantibodies within non-Hodgkin's (NHL) and Hodgkin's lymphoma (HL) patients has been investigated.
  • Afterwards, the results between the two lymphoma groups have been confronted.
  • CONCLUSION: In conclusion, ANA and related autoantibodies can frequently be detected during lymphoma treatment.
  • However, the majority of lymphoma patients with positive ANA did not display autoimmune diseases, demonstrating the lack of a strict correlation between the presence of ANA and autoimmune diseases.
  • [MeSH-major] Antibodies, Antinuclear / blood. Autoimmune Diseases / diagnosis. Hodgkin Disease / immunology. Lymphoma, Non-Hodgkin / immunology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Minerva Med. 2008 Aug;99(4):417 [18663350.001]
  • (PMID = 18299692.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Autoantigens; 0 / Biomarkers; 0 / Jo-1 antibody; 0 / Nuclear Proteins; 0 / Ribonucleoproteins, Small Nuclear; 0 / Scl 70 antigen, human; 0 / snRNP Core Proteins; EC 3.1.- / Exoribonucleases; EC 3.1.- / Exosome Multienzyme Ribonuclease Complex; EC 3.1.13.- / EXOSC10 protein, human
  •  go-up   go-down


25. Berrutti M, Pellicano R, Rizzetto M: One question on the work on antinuclear antibody levels in patients with Hodgkin's and non-Hodgkin's lymphoma. Minerva Med; 2008 Aug;99(4):417
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One question on the work on antinuclear antibody levels in patients with Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / microbiology. Lymphoma, Non-Hodgkin / microbiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Minerva Med. 2008 Feb;99(1):7-14 [18299692.001]
  • (PMID = 18663350.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear
  •  go-up   go-down


26. Maccormick RE: Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses; 2006;67(2):212-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is curative for a small number of malignancies including childhood leukemia, Hodgkin's and non-Hodgkin's lymphoma, and germ cell malignancies.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546325.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


27. Hemminki K, Eng C, Chen B: Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab; 2005 Oct;90(10):5747-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hurthle cell tumors were associated with Hodgkin's and non-Hodgkin's lymphoma, but the numbers of cases were small.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030170.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Ries F, Ferster A, Rieux-Laucat F, Biwer A, Dicato M: Autoimmune lymphoproliferative syndrome (ALPS). Case report and family history. Bull Soc Sci Med Grand Duche Luxemb; 2010;(2):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune lymphoproliferative syndrome (ALPS) is a rare disease caused by defective lymphocyte apoptosis and is characterized by non-malignant lymphoproliferation, hepatosplenomegaly, autoimmune manifestations and increased risk of both Hodgkin's and non-Hodgkin's lymphoma.

  • Genetic Alliance. consumer health - Autoimmune Lymphoproliferative Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882745.001).
  • [ISSN] 0037-9247
  • [Journal-full-title] Bulletin de la Société des sciences médicales du Grand-Duché de Luxembourg
  • [ISO-abbreviation] Bull Soc Sci Med Grand Duche Luxemb
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Luxembourg
  •  go-up   go-down






Advertisement